PDF 242kWORD 46k

pursuant to Rule 133 of the Rules of Procedure

on the vaccine against the H1N1 virus

Mireille D’Ornano

Motion for a European Parliament resolution on the vaccine against the H1N1 virus  

The European Parliament,

–  having regard to Article 168 of the Treaty on the Functioning of the European Union,

–  having regard to Rule 133 of its Rules of Procedure,

A.  whereas a number of vaccines against the H1N1 virus have been granted EU marketing authorisation, in particular the Pandemrix vaccine (‘the vaccine’) on 25 May 2008;

B.  whereas a study produced by the VAESCO project in July 2011 has revealed a link between administration of the vaccine and an increased risk of narcolepsy, particularly in subjects below the age of 19;

C.  whereas, moreover, the vaccine is associated with an increased risk of Guillain-Barré syndrome, and whereas the use of squalene-based adjuvants can lead to an increased risk of contracting auto-immune diseases;

1.  Notes the World Health Organisation's opinions on the vaccine (2009) and that of the European Medicines Agency as updated in May 2016;

2.  Urges the Commission nonetheless to produce a conclusive study on the links between the vaccine and the aforementioned health risks, drawing in particular on the work of the European Medicines Agency;

3.  Urges it to amend the recommendations on the vaccine accordingly.

Legal notice - Privacy policy